What’s that “Universal Antidote” Pitched by Marc Lichtenfeld?

By Travis Johnson, Stock Gumshoe, July 27, 2016

This stock certainly has Gumshoe Nation in a bit of a lather… though it’s also one that many of you already know about, and the solution to this teaser is not super-secret (it has been posted in recent discussions here at Stock Gumshoe a few times).

Marc Lichtenfeld puts out a newsletter advisory called Lightning Trend Trader for the Oxford Club, and his latest pitch is like so many in the world of biotech: He says it’s going to save lives and make you extraordinarily wealthy… so you get to be rich, and you get to feel extra good about your wealth because you helped to fund lifesaving work!

Life (and investing) is rarely so simple as that, of course, particularly in the highly volatile world of biotech stocks (exhibit A being Lichtenfeld’s guarantee that ALNY would double when it was around $130… it has instead halved in the biotech washout) … but let’s look into the promise Lichtenfeld is peddling this time…

“The greatest biotech stock story of this decade is about to hit the markets right now.

“To put it simply, one under-the-radar company is about to release a “universal antidote” that could likely save up to 1.5 million lives this year…

“And every year after.

“When it does, it could add $1 billion to its revenues…

“And send the stock soaring 8,233% over the long term… possibly even higher.”

Geez, that’s only $666 bucks for each life saved! So what is this “universal antidote,” you ask? More clues:

“… every year, as many as 1.5 million people suffer from a severe medical event – one that requires immediate attention.

“Worst of all, many of them are unable to beat this highly preventable cause of death…

“One that has NOTHING to do with infection… heart attacks… or even human error….

“Most of these deaths are unrelated to the illness or condition that patients are being treated for….

“A miraculous new drug – with an incredible patent moat… and zero competition – is on the brink of eliminating these untimely deaths once and for all…”

There are some pull quotes from doctors and well-known medical journals thrown in at this point, largely to give some weight to the promise — if the New England Journal of Medicine calls it “a potential universal antidote,” the copywriter thinks, that means a lot more than Marc Lichtenfeld calling it a universal antidote.

This is an important point when we should mention what “universal antidote” means, however. An antidote is a counteragent to a drug or a poison (many drugs in the wrong dose or the wrong patient, of course, might be considered poisonous).

So… does this “universal antidote” mean it will counteract all drugs? Uh, no. That’s essentially impossible (I feel pretty confident saying that, even though I’m too much of a dummy to understand much in the world of biology and drug development). And, of course, a “universal antidote” could perhaps save a lot more than 1.5 million people.

But apparently it is an antidote to something that causes “a severe medical event”.

Any more clues?

“It’s based on the results of a 13-year collaboration of award-winning scientists who come from Harvard, Yale, Johns Hopkins and more.

“And, thanks to this drug’s dramatic life-changing potential, it’s already been designated as a breakthrough therapy AND has been granted an Accelerated Approval pathway by the FDA….

“early trial results show that this drug is immensely effective.

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“It’s capable of achieving results in as little as two minutes…

“… if you want a shot at seeing results like these, you must get in before August 17.

“You see, Lightning is about to strike for this little-known company…

“And when it does, I estimate – based on the sales figures alone – that it will surge 8,233% higher. (I’ll show you why that could even be a conservative guess in just a moment.)

“By the end of this summer, you could find this one-of-a-kind drug at every hospital across the nation.

“Let me be clear… it has absolutely NO competition. No alternative.

“And it’s surrounded by patents… protected from competition for the next 15 years or more.

“Dr. Jerrold Levy of Duke University predicts that once available, all hospitals will stock the universal antid